Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease.

Article Details

Citation
Copy to clipboard

Iznardo H, Puig L

Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease.

Int J Mol Sci. 2021 Apr 21;22(9). pii: ijms22094344. doi: 10.3390/ijms22094344.

PubMed ID
33919434 [ View in PubMed
]
Abstract

Unmet needs in the treatment of psoriasis call for novel therapeutic strategies. Pustular psoriasis and psoriatic arthritis often represent a therapeutic challenge. Focus on IL-36 cytokines offers an interesting approach, as the IL-36 axis has been appointed a critical driver of the autoinflammatory responses involved in pustular psoriasis. Two IL-36R blocking antibodies, imsidolimab and spesolimab, are currently undergoing phase II and III clinical trials, with promising results.

DrugBank Data that Cites this Article

Drugs